State-of-the-Art and Novel Approaches in Molecular and Translational Medicine in Europe
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: closed (15 January 2025) | Viewed by 18605
Special Issue Editor
Special Issue Information
Dear Colleagues,
The rapid advancement of technology has led to the establishment of high throughput and state-of-the-art techniques that benefit biomedicine research. There is a growing interest in unraveling the mechanistic basis of pathophysiological backgrounds, identifying accurate and easy-to-detect biomarkers, and finding novel promising therapies through the use of omics technologies, bioinformatics analyses, and other technological breakthroughs. In this context, the panoply of data that arise from the combination of new and established techniques can pave the way for the reappraisal of several medical states through novel approaches for the identification or treatment of pathophysiological conditions.
In this Special Issue, European experts in the field of biomedicine are invited to present the progress of translational medicine in our continent through the use of novel or state-of-the-art approaches in the fields of molecular, cellular, and biochemical medicine. These approaches may include high throughput techniques, in vitro and in vivo models of disease/physiology, bioinformatic tools and novel therapeutics, as well as unique approaches for studying biomedical issues.
Dr. Vasileios Tzounakas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- translational medicine
- biomarkers
- high throughput techniques
- bioinformatics
- in vitro and in vivo models
- novel therapies
- research applications in pathophysiological backgrounds
- molecular/biochemical disease characterization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.